News News Details

2019年度金融人物朱晋桥:响应党的号召“不忘初心,牢记使命”,科技兴国,医疗健国

Date: 2019-12-04
Views: 10
2019中国经济年度峰会暨2019(第三届)中国金融与投资高层论坛在北京举行,现场颁发了“2019中国金融年度人物”重磅奖项,仅有5人入选,中国财产再保险有限责任公司总经理张仁江,国信证券股份有限公司董事长何如,北京农村商业银行股份有限公司董事长王金山,泸州市兴泸股权投资基金管理有限公司董事长陈兵,深圳市倚锋投资管理企业(有限合伙)董事长朱晋桥等一同名列榜单。 


2019年度金融人物朱晋桥:响应党的号召“不忘初心,牢记使命”,科技兴国,医疗健国



2019年度金融人物朱晋桥:响应党的号召“不忘初心,牢记使命”,科技兴国,医疗健国
倚锋资本董事长朱晋桥先生表示:


“响应党的号召不忘初心,牢记使命,科技兴国,医疗健国。科创板肩负着振兴中华的使命,硬科技是国家的核心竞争力,是资本市场具有跨时代意义的变革,倚锋资本会一如既往鼓励支持高研发投入的创新药企业,助力中国医药产业的良性发展。”



2019年度金融人物朱晋桥:响应党的号召“不忘初心,牢记使命”,科技兴国,医疗健国

会议现场



本次参会嘉宾包括:第九届、十届、十一届全国政协副主席白立忱出席活动,十一届全国人大财经委副主任贺铿、原国有重点大型企业监事会主席季晓南、经济日报社原总编辑冯并、中国商报社中国商网总编辑胡斌、《市场观察》杂志社总编辑刘彤、塞内加尔驻华大使馆公使玛玛杜·萨拉、中国人民大学企业创新发展研究中心主任姚建明、经济日报《中国经济信息》杂志社原社长王亚东、《经济》杂志社副社长王琤以及来自全国各地的优秀企业家、经济领域的知名专家学者、财经主流媒体代表等400余人出席本次论坛,论坛由组委会副秘书长、财经专栏作家、双语主持人龙煦霏全程主持。




Related News / Recommended news More
2022 - 08 - 10
On August 9, the National Health Commission issued a notice, according to the approval opinions of the State Food and Drug Administration on the application for registration of additional indications for the treatment of novel coronavirus pneumonia with azvudine tablets. In order to further improve the antiviral treatment scheme for novel coronavirus pneumonia, the drug was included in the diagnos...
2022 - 08 - 05
Just recently, the Hong Kong Stock Exchange welcomed the successful submission of the first share of the new crown oral drug. On August 4, the Hong Kong Stock Exchange disclosed that Henan Zhenzhen Biotechnology Co., Ltd. (hereinafter referred to as 'Genuine Biotech') submitted a listing application to the Hong Kong Stock Exchange. Efung Capital is the only investment institution...
2022 - 08 - 01
Recently, Apexigen, a portfolio company of Efung Capital, and Brookline Capital Acquisition Corp.-a Special Purpose Acquisition Company (SPAC)-entered an official merger process, resulting that Brookline Capital Acquisition Corp. was renamed to Apexigen, Inc. Guided and led by Dr. Xiaodong Yang, president as well as Chief Executive Officer (CEO) of Apexigen company, the firm joined the listing of ...
2022 - 07 - 25
On July 25, 2022, the State Drug Administration proclaimed that, in accordance with the relevant provisions of the Drug Administration Law and specific drug approval procedures, the State Drug Administration conducted emergency review and approved Henan Zhenzhen Biotechnology Co., Ltd. with certain conditions. The registration application for Azvudine tablets to treat the novel coronavirus pneumon...
Address: 505 China Resources Building, 2666 Keyuan South Road, Nanshan District, Shenzhen
TEL:0755-8831-6141
E-mail:info@efungcapital.com
Copyright ©2018 - 2021 Shenzhen Efung Investment Management Co. Ltd.
Rhino Cloud provides enterprise cloud services
犀牛云提供云计算服务